HR Execs on the Move

Aurobindo Pharma USA

www.aurobindousa.com

 
Aurobindo USA is committed to delivering a broad portfolio of quality, affordable generic pharmaceuticals to pharmacists and patients. Since its first US ANDA approval in 2004, Aurobindo has expanded its portfolio to include more than 125 product families and 450 individual product packages, representing a wide range of therapeutic categories. Aurobindo has been recognized as the fastest growing pharmaceutical company in 2012,* and in early 2013, thanks to the ongoing support of our customers, became one of the top 10 pharmaceutical companies, brand or generic, in terms of total prescriptions dispensed.**
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Strategyx

Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protemix

Protemix is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeWays

LifeWays is the Community Mental Health Agency for Jackson and Hillsdale Counties. We provide specialty mental health services to individuals with Medicaid or Healthy Michigan, living in Jackson or Hillsdale County. Once someone receives a screenin...

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.